Literature DB >> 30676073

Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics.

Lenneke Minjon1, Els van den Ban2, Emma de Jong1, Patrick C Souverein1, Toine C G Egberts1,3, Eibert R Heerdink1,3,4.   

Abstract

OBJECTIVES: To characterize reported adverse drug reactions (ADRs) in children and adolescents treated with antipsychotics and determine differences in relative reporting frequency between genders, age classes, and reporter types.
METHODS: Individual case safety reports of children ages 1 - 17 years in whom an antipsychotic drug was the suspected or interacting drug from the worldwide database, VigiBase, from 1968 until March 2017, were included. Reported ADRs were categorized based on the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries and clinical reasoning. Proportional reporting ratios (PRRs) and 95% confidence intervals (95% CIs) were calculated for genders, age classes, and reporter types.
RESULTS: In total, 45,201 reported ADRs were included. The most frequently reported were ADRs related to extrapyramidal syndrome (14.7%), breast disorders or blood prolactin level changes (4.7%), and cardiac arrhythmias (4.6%). Differences in relative reporting frequencies were observed between age classes and reporter types, and less prominent between genders. For example, ADRs related to hyperglycemia/new-onset diabetes mellitus were less frequently reported in children ages 1 - 5 than in children ages 12 - 17 (PRR: 0.4, 95% CI: 0.2 - 0.5). ADRs related to cardiac arrhythmias were less frequently reported by consumers compared with health care professionals (PRR: 0.5, 95% CI: 0.5 - 0.6), whereas ADRs related to a change in weight/body mass index were more frequently reported by consumers (PRR: 3.2, 95% CI: 2.9 - 3.5).
CONCLUSION: A wide spectrum of ADRs were reported in children treated with antipsychotics. The relative differences in reporting frequency between age classes and reporter types can be of help to tailor information about possible ADRs and to monitor for ADRs.

Entities:  

Keywords:  adolescent; adverse drug reaction; antipsychotic agents; child; pharmacovigilance

Mesh:

Substances:

Year:  2019        PMID: 30676073     DOI: 10.1089/cap.2018.0139

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  10 in total

Review 1.  Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.

Authors:  Diane Merino; Arnaud Fernandez; Alexandre O Gérard; Nouha Ben Othman; Fanny Rocher; Florence Askenazy; Céline Verstuyft; Milou-Daniel Drici; Susanne Thümmler
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

2.  Parents' satisfaction with information received on psychotropic drugs used by adolescents in a Mental Health Unit.

Authors:  Dafny Oliveira de Matos; Patrícia Medeiros-Souza; Renata Passos de Melo; Ricardo Azevedo de Menezes; Noemia Urruth Leão Tavares
Journal:  Rev Paul Pediatr       Date:  2022-05-11

3.  Characteristics of voluntary reporting of adverse drug events related to antipsychotics in Australia: 14-year analysis.

Authors:  Hanan Khalil; Dimi Hoppe; Nabil Ameen
Journal:  Ther Adv Drug Saf       Date:  2021-05-29

4.  Monitoring of Adverse Drug Reaction-Related Parameters in Children and Adolescents Treated With Antipsychotic Drugs in Psychiatric Outpatient Clinics.

Authors:  Lenneke Minjon; Ivona Brozina; Toine C G Egberts; Eibert R Heerdink; Els van den Ban
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

5.  We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database.

Authors:  Concetta Rafaniello; Maria Giuseppa Sullo; Carla Carnovale; Marco Pozzi; Barbara Stelitano; Sonia Radice; Renato Bernardini; Francesco Rossi; Emilio Clementi; Annalisa Capuano
Journal:  Front Psychiatry       Date:  2020-12-02       Impact factor: 4.157

6.  The effect of acupuncture on condition being studied emotional disorders in patients with postpartum: A protocol for systematic review and meta-analysis.

Authors:  Ning Luo; Yiyi Wang; Yunfan Xia; Mingqi Tu; Xiaoting Wu; Xiaomei Shao; Jianqiao Fang
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

7.  Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners.

Authors:  Lenneke Minjon; Els van den Ban; Marloes T Bazelier; Arief Lalmohamed; Toine C G Egberts; Eibert R Heerdink
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-10-07       Impact factor: 2.576

Review 8.  Clarity and applicability of adverse drug reaction-related monitoring instructions in clinical practice guidelines for children and adolescents treated with antipsychotic drugs: a review of six clinical practice guidelines.

Authors:  Lenneke Minjon; Juul W Aarts; Els van den Ban; Toine Cg Egberts; Eibert R Heerdink
Journal:  BMJ Open       Date:  2022-03-08       Impact factor: 2.692

9.  Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice.

Authors:  Karin M Egberts; Manfred Gerlach; Christoph U Correll; Paul L Plener; Uwe Malzahn; Peter Heuschmann; Stefan Unterecker; Maike Scherf-Clavel; Hans Rock; Gisela Antony; Wolfgang Briegel; Christian Fleischhaker; Alexander Häge; Tobias Hellenschmidt; Harmut Imgart; Michael Kaess; Andreas Karwautz; Michael Kölch; Karl Reitzle; Tobias Renner; Su-Yin Reuter-Dang; Christian Rexroth; Gerd Schulte-Körne; Frank M Theisen; Susanne Walitza; Christoph Wewetzer; Stefanie Fekete; Regina Taurines; Marcel Romanos
Journal:  Pharmacopsychiatry       Date:  2022-02-07       Impact factor: 2.544

10.  Trends Over Time in Antipsychotic Initiation at a Large Children's Health Care System.

Authors:  Laura J Chavez; Kelly J Kelleher; Arne Beck; Gregory N Clarke; Robert B Penfold
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-06       Impact factor: 3.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.